In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a rating on Ironwood Pharma (NASDAQ: IRWD). The company’s shares opened today at $17.59.
Currently, the analyst consensus on Ironwood Pharma is Strong Buy and the average price target is $19.33, representing a 9.9% upside.
In a report issued on July 21, Wells Fargo also maintained a Buy rating on the stock with a $19 price target.
Based on Ironwood Pharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $52.17 million and GAAP net loss of $52.5 million. In comparison, last year the company earned revenue of $54.35 million and had a GAAP net loss of $21.7 million.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2017, Thomas Mccourt, the CCO of IRWD sold 30,000 shares for a total of $546,000.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. It discovers, develops and intends to commercialize differentiated medicines that improve patient’s lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation.